

Triptorelin acetate(57773-63-4 free base)

Chemical Properties


CAS No. : 140194-24-7

Formula: C66H86N18O15

Molecular Weight: 1371.53

Storage: Keep away from moisture,Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Triptorelin acetate(57773-63-4 free base) (CL 118,532) is used as a GnRH agonist. It decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by causing constant stimulation of the pituitary. Triptorelin acetate(57773-63-4 free base) may be used in the treatment of hormone-responsive cancers such as breast cancer or prostate cancer, precocious puberty, estrogen-dependent conditions, and assisted reproduction.
Targets(IC50)	GNRH Receptor

Solubility Information

Solubility	H2O: Insoluble, DMSO: 250 mg/mL (182.28 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 10 mg/mL (7.29 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.7291 mL	3.6456 mL	7.2911 mL
5 mM	0.1458 mL	0.7291 mL	1.4582 mL
10 mM	0.0729 mL	0.3646 mL	0.7291 mL
50 mM	0.0146 mL	0.0729 mL	0.1458 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. *J Pediatr Endocrinol Metab.* 2016 Feb 17. pii: /j/jpem.ahead-of-print/jpem-2015-0376/jpem-2015-0376.xml. doi: 10.1515/jpem-2015-0376. [Epub ahead of print] PubMed PMID: 26887034.

Meattini I, Saieva C, et al. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin. *Future Oncol.* 2016 Mar;12(5):625-35. doi: 10.2217/fo.15.357. Epub 2016 Feb 3. PubMed PMID: 26837239.

Bellet M, Gray KP, Francis PA, et al. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. *J Clin Oncol.* 2016 Jan 4. pii: JCO612259. [Epub ahead of print] PubMed PMID: 26729437.

Lambertini M, Boni L, Michelotti A, et al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. *JAMA.* 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291. PubMed PMID: 26720025.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481